TISSEEL- fibrinogen human and thrombin human
TISSEEL FROZEN- fibrinogen human and thrombin human solution
Baxter Healthcare Corporation
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use TISSEEL safely and
effectively. See full prescribing information for TISSEEL.
TISSEEL [Fibrin Sealant] For Topical Use Only Frozen solution and lyophilized powder for solution for topical application Initial U.S. Approval: 1998 RECENT MAJOR CHANGESIndications and Usage (1) 09/2013 INDICATIONS AND USAGE
DOSAGE AND ADMINISTRATIONDOSAGE FORMS AND STRENGTHSCONTRAINDICATIONSWARNINGS AND PRECAUTIONS
ADVERSE REACTIONSHypersensitivity or allergic/anaphylactoid reactions have occurred (6) To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare Corporation at 1-866-888-2472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONSOxidized cellulose-containing preparations can reduce the efficacy of TISSEEL and should not be used as carrier materials (7) USE IN SPECIFIC POPULATIONSPregnancy: No human or animal data. Use only if clearly needed (8.1) See 17 for PATIENT COUNSELING INFORMATION. Revised: 9/2009 |
TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. TISSEEL is effective in heparinized patients.
FOR TOPICAL USE ONLY – DO NOT INJECT
Vials and pre-filled syringes are for single use only. Discard any unused product.
DO NOT EXPOSE TO TEMPERATURES ABOVE 37°C
DO NOT MICROWAVE
DO NOT REFRIGERATE OR FREEZE
AFTER RECONSTITUTION
Do not use iodine or heavy metal containing preparations such as betadine for disinfection of vial stoppers.
Allow alcohol-based disinfectants to evaporate before puncturing stopper.
Use separate syringes and transfer devices for reconstituting Sealer Protein and Thrombin solutions and for application to prevent clotting.
The product must be used within 4 hours after reconstitution.
Freeze-dried Sealer Protein Concentrate and Thrombin are reconstituted in Fibrinolysis Inhibitor Solution and Calcium Chloride Solution, respectively. The Sealer Protein Solution and Thrombin Solution are then combined using the DUPLOJECT Preparation and Application System, or an equivalent delivery device cleared by FDA for use with TISSEEL, to form the Fibrin Sealant.
Prewarming TISSEEL Kit with FIBRINOTHERM
See FIBRINOTHERM manual for complete operating instructions. If a FIBRINOTHERM device is not available, contact Baxter (1-800-423-2090) for assistance.
Preparation of Sealer Protein Solution with FIBRINOTHERM
Notes:
-If the Sealer Protein Concentrate has not fully dissolved within 20 minutes discard the vial and prepare a fresh kit.
-Keep the Sealer Protein Solution at 37°C without stirring. Stir shortly before drawing up the solution to ensure homogeneity.
Preparation of Thrombin Solution with FIBRINOTHERM
To reconstitute the Thrombin (Human) with the Calcium Chloride Solution; follow steps 1-3 under Preparation of Sealer Protein with FIBRINOTHERM utilizing the Thrombin and Calcium Chloride vials.
Transferring to the Sterile Field
For transfer of the Sealer Protein and Thrombin Solutions to the sterile field, the circulating nurse should disinfect the tops of the vials with a germicidal solution and allow to dry. The scrub nurse should withdraw the sterile solutions while the circulating nurse holds the non-sterile vials. Slowly withdraw the solution, by firm constant aspiration, to reduce the risk of large air bubbles.
DO NOT EXPOSE TO TEMPERATURES ABOVE 37°C
DO NOT MICROWAVE
DO NOT REFRIGERATE OR
RE-FREEZE
Do not use TISSEEL (frozen) until it is completely thawed and warmed (liquid consistency) to 33-37ºC.
Do not remove the protective syringe cap until use.
Sterile Water Bath (Quick Thawing): Transfer inner pouch to the sterile field, remove pre-filled syringe from inner pouch and place directly into sterile water bath ensuring the syringe is completely immersed in the water. Maintain the product at 33-37°C until use. If the package is opened or warmed to 33-37°C, it must be used within 4 hours.
Non-Sterile Water Bath: Maintain the pre-filled syringe in pouches and place into a water bath outside the sterile field ensuring the pouches remain submerged. Remove from the water bath after thawing and warming, dry the external pouch and transfer inner pouch with pre-filled syringe onto the sterile field. Maintain the product at 33-37°C until use. If the package is opened or warmed to 33-37°C, it must be used within 4 hours.
Incubator: Maintain the pre-filled syringe in pouches and place into an incubator. Remove from the incubator after thawing and warming. Transfer inner pouch with pre-filled syringe onto the sterile field. Maintain the product at 33-37°C until use. If the package is opened or warmed to 33-37°C, it must be used within 4 hours.
| Pack Size |
Sterile Water Bath |
Non-Sterile Water Bath (In Pouches) 33 - 37°C |
Incubator (In Pouches) 33 - 37°C |
| 2 mL | 5 minutes | 30 minutes | 40 minutes |
| 4 mL | 5 minutes | 40 minutes | 85 minutes |
| 10 mL | 12 minutes | 80 minutes | 105 minutes |
Room Temperature Thawing: Unopened pouches can be stored for up to 48 hours at room temperature (15-25°C). Before use, warm the product to 33-37ºC and apply immediately. The total thawing and warming time cannot exceed 48 hours.
| Pack Size |
Room Temperature (In Pouches) 15 – 25oC |
| 2 mL | 60 minutes |
| 4 mL | 110 minutes |
| 10 mL | 160 minutes |
| Pack Size |
Sterile Water Bath |
Non-Sterile Water Bath (In Pouches) 33 – 37°C |
Incubator (In Pouches) 33 – 37°C |
| 2 mL | 2 minutes | 16 minutes | 20 minutes |
| 4 mL | 2 minutes | 21 minutes | 43 minutes |
| 10 mL | 6 minutes | 43 minutes | 52 minutes |
Dry the site of application as much as possible.
Apply TISSEEL as a thin layer by dripping or spraying using a cannula or spray set. The treating physician will determine the amount of TISSEEL to be applied based on the surface to be covered. Ensure that the amount applied is sufficient to entirely cover the intended application area. The approximate surface areas covered by each package size of TISSEEL are listed in Table 4:
|
Required package size of TISSEEL |
Maximum coverage using spray | Maximum coverage using cannula |
|
2 mL 4 mL 10 mL |
100 cm2 200 cm2 500 cm2 |
8 cm2 16 cm2 40 cm2 |
Avoid application beyond the intended area. Allow at least 2 minutes after application to achieve sufficient polymerization. If repeat application is needed, dry the site as much as possible before reapplying. Reapply after removing residues from the prior application or before polymerization takes place since TISSEEL may not adhere firmly to a polymerized layer.
In cases where very small volumes (1-2 drops) are required, expel and discard the first several drops from the application cannula immediately before application to ensure administration of adequately mixed TISSEEL.
Exercise caution when applying TISSEEL using pressurized gas (see Warnings and Precautions (5.2)).
Record the product name, batch number and patient information for traceability purposes.
TISSEEL Kit (Freeze-Dried)
Apply TISSEEL using the DUPLOJECT Fibrin Sealant Preparation and Application System or an equivalent delivery device (including open and minimally invasive spray devices) cleared by FDA for use with TISSEEL. Specific instructions for the use of TISSEEL in conjunction with each cleared delivery device are provided with the device.
TISSEEL Pre-filled Syringe (Frozen)
Apply pre-filled TISSEEL using the DUO Set accessory devices provided with the product or an equivalent delivery device (including open and minimally invasive spray devices) cleared by FDA for use with TISSEEL.
DUO Set Instructions (see Figure 1 below):
Note: Interruption of TISSEEL application causes clogging in the cannula. Replace the cannula immediately prior to resuming application. If the opening of the joining piece (Y connector) facing the cannula is clogged, use the spare joining piece provided in the package.
Figure 1 DUO SET
TISSEEL Kit (Freeze-Dried) is supplied as 2 mL, 4 mL and 10 mL (total volume) pack sizes with and without the DUPLOJECT System.
TISSEEL Pre-Filled Syringe (Frozen) is supplied as 2 mL, 4 mL and 10 mL (total volume) pack sizes with the DUO Set.
Do not inject TISSEEL directly into the circulatory system or into highly vascularized tissue. Intravascular application of TISSEEL can lead to intravascular coagulation, can result in life-threatening thromboembolic events, and can increase the likelihood and severity of acute hypersensitivity reactions in susceptible patients(see Warnings and Precautions (5.3) and Adverse Reactions (6.2)).
Hypersensitivity or allergic/anaphylactoid reactions can occur with the use of TISSEEL. Cases (<1/10,000) have been reported in post marketing experience with Baxter's fibrin sealant (see Adverse Reactions (6.2)). In specific cases, these reactions have progressed to severe anaphylaxis. Such reactions may especially be seen if TISSEEL is applied repeatedly over time or in the same setting, or if systemic aprotinin has been administered previously. Even if the first treatment was well tolerated, this may not exclude the occurrence of an allergic reaction after a subsequent administration of TISSEEL or systemic aprotinin. Observed symptoms of allergic anaphylactic reactions to TISSEEL have included: bradycardia, tachycardia, hypotension, flushing, bronchospasm, wheezing, dyspnea, nausea, urticaria, angioedema, pruritus, erythema and paresthesia. Such reactions can also occur in patients receiving TISSEEL for the first time.
Aprotinin is included in TISSEEL for its antifibrinolytic properties. Aprotinin, a protein, is known to be associated with anaphylactic reactions. Even in the case of strict local application of aprotinin, there is a risk of anaphylactic reactions to aprotinin, particularly in the case of previous exposure (see Contraindications (4.2)). TISSEEL does not contain any substances of bovine origin.
Discontinue administration of TISSEEL in the event of hypersensitivity reactions. Mild reactions can be managed with antihistamines. Severe hypotensive reactions require immediate intervention using current principles of shock therapy. Remove remaining product from the application site.
Air or gas embolism has occurred when fibrin sealant was administered using pressurized gas. This can occur if a spray device is used at higher than recommended pressures and in close proximity to the tissue surface.
When applying TISSEEL using a spray device, be sure to use the pressure within the pressure range recommended by the spray device manufacturer. In the absence of a specific recommendation avoid using pressure above 20-25 psi. Do not spray closer than the distance recommended by the spray device manufacturer. In the absence of a specific recommendation avoid spraying closer than 10-15 cm from the surface of the tissue. When spraying TISSEEL, changes in blood pressure, pulse, oxygen saturation and end tidal CO2 should be monitored because of the possibility of occurrence of air or gas embolism. When using the EASYSPRAY device, or an equivalent spray device for open surgical procedures cleared by FDA, TISSEEL must not be sprayed in enclosed body areas and must be sprayed onto only visible application sites.
The sealer protein and thrombin solutions are denatured by alcohol, iodine or heavy metal ions. If any of these substances have been used to clean the wound area, the area must be thoroughly rinsed before the application of TISSEEL.
Apply TISSEEL as a thin layer as excess clot thickness can negatively interfere with wound healing.
To minimize the risk of intravascular application, exercise caution when using TISSEEL in surgery (see Contraindications (4.1) and Adverse Reactions (6.2)).
The safety and effectiveness of TISSEEL used alone or in combination with biocompatible carriers in neurosurgical procedures or other surgeries involving confined spaces have not been evaluated, and its use in this setting is not approved by FDA (see Adverse Reactions (6.2) and Drug Interactions (7)).
TISSEEL is made from human plasma. Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically the Creutzfeldt-Jakob disease (CJD) agent. All infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Baxter Healthcare Corporation, telephone # 1-866-888-2472.
Hypersensitivity or allergic/anaphylactoid reactions have occurred. In isolated cases, these reactions have progressed to severe anaphylaxis (see Warnings and Precautions (5.1)). No adverse events of this type were reported during clinical trials.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Increased D-Dimer levels have been observed during a clinical study in cardiovascular surgery (see Clinical Studies (14)), but did not exceed values reported in the literature occurring after this type of surgery. Postoperatively increased D-Dimers can result at least partly from the degradation of Fibrin Sealant.
There were no reports of serious, associated adverse reactions reported above 1% in clinical studies.
Because adverse reactions are reported voluntarily and the population is of uncertain size, it is not always possible to reliably estimate the frequency of these reactions.
The following adverse reactions have been reported in the post-marketing experience.
IMMUNE SYSTEM DISORDERS: Hypersensitivity,
including anaphylactic reaction and anaphylactic shock.
Anaphylactic reactions and anaphylactic shock have included
fatal outcomes.
VASCULAR
DISORDERS: hypotension, thromboembolism, including
cerebral artery embolism, cerebral infarction*
SKIN AND SUBCUTANEOUS TISSUE
DISORDERS: angioedema, erythema, impaired wound
healing, pruritus, urticaria
CARDIAC DISORDERS: bradycardia, tachycardia
RESPIRATORY DISORDERS: bronchospasm, dyspnea, wheezing
GASTROINTESTINAL DISORDERS: nausea
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS: flushing, paresthesia
Class Effect: Air embolism has occurred with misapplication of fibrin sealant using the spray device. A post marketing fatality was reported in association with the use of another fibrin sealant when applied using a spray device. The case involved an attempt to stop active bleeding by applying the fibrin sealant using a spray device attached to a wall unit at a higher than recommended pressure for the spray device. In addition, the spray head was placed at a distance from the bleeding site that was closer than the recommended distance guidelines for the application of the sealant. The patient suffered a fatal air embolism.
Manifestations of hypersensitivity or allergic reactions associated with the class of fibrin sealant/hemostatic products include: application site irritation, chest discomfort, chills, headache, lethargy, restlessness and vomiting. There have been no reports of these reactions related to the specific use of TISSEEL.
There have been reports of serious adverse events such as paralysis and other compressive complications possibly related to the use of fibrin sealants in combination with resorbable hemostatic agents. There have also been reports of fatalities following the misadministration of topical thrombin (see Warnings and Precautions (5.4)).
Oxidized cellulose-containing preparations can reduce the efficacy of TISSEEL and should not be used as carrier materials.
No interaction studies have been performed.
Pregnancy Category C
Animal reproduction studies have not been conducted with TISSEEL. It is also not known whether TISSEEL can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Some viruses, such as parvovirus B19, are particularly difficult to remove or inactivate at this time. Parvovirus B19 most seriously affects pregnant women (fetal infection). TISSEEL should be given to a pregnant woman only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TISSEEL is administered to nursing mothers.
Limited clinical study data are available with regard to the use of TISSEEL in children. Of 365 patients undergoing repeated cardiac surgery or emergency resternotomy in a clinical trial of TISSEEL, 27 pediatric patients aged 16 years or younger were treated with TISSEEL. Of these, 2 patients were less than 6 months, 2 patients were between the ages of 6 months and 2 years, 15 patients were between 3-11 years of age, and 8 patients were between 12-16 years of age. There were no differences in safety observed between these subjects and the overall population. (see Clinical Studies (14)).
Clinical studies included 218 patients aged 65 years of age or older treated with TISSEEL (159 undergoing cardiac surgery and 59 undergoing vascular surgery) (see Clinical Studies (14)). No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
TISSEEL [Fibrin Sealant] is a two-component fibrin sealant made from pooled human plasma. When combined, the two components, Sealer Protein and Thrombin mimic the final stage of the blood coagulation cascade.
Sealer Protein (Human)
Sealer Protein (Human) is a sterile, non-pyrogenic, vapor heated and solvent/detergent treated preparation made from pooled human plasma. Sealer Protein (Human) is provided either as a freeze-dried powder for reconstitution with Fibrinolysis Inhibitor Solution or as a finished frozen solution pre-filled into one side of a dual-chambered syringe. The active ingredient in Sealer Protein (Human) is fibrinogen. Sealer Protein (Human) solution contains fibrinolysis inhibitor, synthetic Aprotonin, that delays fibrinolysis. Aprotinin (Synthetic) is manufactured by solid phase synthesis from materials completely of non-human/non-animal origin.
Thrombin (Human)
Thrombin (Human) is a sterile, non-pyrogenic, vapor heated and solvent/detergent treated preparation made from pooled human plasma. Thrombin (Human) is also provided either as a freeze-dried powder for reconstitution with Calcium Chloride Solution or as a finished frozen solution pre-filled into one side of a dual-chambered syringe.
The reconstituted solution or pre-filled syringe contains:
Sealer Protein Solution
Thrombin Solution
* The potency expressed in units is determined with a clotting assay using an in-house internal standard that has been calibrated against the World Health Organization (WHO) Second International Standard for Thrombin, 01/580. Therefore, a unit (U) is equivalent to an International Unit (IU).
TISSEEL is made from pooled human plasma collected at US licensed collection centers. The vapor heat and solvent/detergent treatment steps used in the manufacturing process have been shown to be capable of significant viral reduction. No procedure, however, has been shown to be completely effective in removing viral infectivity from derivatives of human plasma (see Warnings and Precautions (5.5)). Validation studies were conducted using samples drawn from manufacturing intermediates for each of the two human plasma derived components. These samples were spiked with stock virus suspensions of known titers followed by further processing under conditions representative of respective manufacturing steps.
The virus reduction factors (expressed as log10) of manufacturing steps for each of the viruses tested are shown in Table 5.
| Sealer Protein Component | |||||
| Manufacturing Step | Mean Reduction Factors [log10] of Virus Tested | ||||
| HIV-1 | HAV | BVDV | PRV | MMV | |
| Early Manufacturing Steps | n.d. | n.d. | n.d. | n.d. | 2.7 |
| Solvent/Detergent Treatment | >5.3 | n.d. | >5.7 | >5.9 | n.d. |
| Vapor Heat Treatment | >5.5 | >5.6 | >5.7 | >6.7 | 1.2 |
| Overall Reduction Factor (ORF) | >10.8 | >5.6 | >11.4 | >12.6 | 3.9 |
| Thrombin Component | |||||
| Manufacturing Step | Mean Reduction Factors [log10] of Virus Tested | ||||
| HIV-1 | HAV | BVDV | PRV | MMV | |
| Thrombin Precursor Mass Capture | 3.2 | 1.5 | 1.8 | 2.5 | 1.2 |
| Vapor Heat Treatment | >5.5 | >4.9 | >5.3 | >6.7 | 1.0 |
| Solvent/Detergent Treatment | >5.3 | n.d. | >5.5 | >6.4 | n.d. |
| Ion Exchange Chromatography | n.d. | n.d. | n.d. | n.d. | 3.6 |
| Overall Reduction Factor (ORF) | >14.0 | >6.4 | >12.6 | >15.6 | 5.8 |
n.d. = not determined
HIV-1: Human Immunodeficiency Virus 1; HAV: Hepatitis A Virus; BVDV: Bovine Viral Diarrhea Virus, a model for Hepatitis C Virus; PRV: Pseudorabies Virus, a model for lipid enveloped DNA viruses, among those is Hepatitis B Virus; MMV: Mouse Minute Virus, a model for B19V.
In addition, Human Parvovirus B19 (B19V) was used to investigate the upstream Thrombin precursor mass capture step, the Sealer Protein early manufacturing steps and the Thrombin and Sealer Protein vapor heating steps. Using quantitative PCR assays, the estimated B19V log reduction factors were: (a) 1.7 for the Thrombin precursor mass capture step, (b) 3.4 for Sealer Protein early manufacturing steps, (c) >4 for Thrombin vapor heat treatment and (d) 1.0 for Sealer Protein vapor heat treatment.
Upon mixing Sealer Protein (Human) and Thrombin (Human), soluble fibrinogen is transformed into fibrin, forming a rubber-like mass that adheres to the wound surface and achieves hemostasis and sealing or gluing of tissues. TISSEEL mimics the final coagulation cascade step as it has all relevant components to form a clot. TISSEEL is effective in heparinized patients and in patients medicated with anti-platelet drugs.
Thrombin is a highly specific protease that transforms the fibrinogen contained in Sealer Protein (Human) into fibrin. Fibrinolysis inhibitor, Aprotinin (Synthetic), is a polyvalent protease inhibitor that prevents premature degradation of fibrin. Preclinical studies with different fibrin sealant preparations simulating the fibrinolytic activity generated by extracorporeal circulation in patients during cardiovascular surgery have shown that incorporation of aprotinin in the product formulation increases resistance of the fibrin sealant clot to degradation in a fibrinolytic environment.
Unincorporated Aprotinin and its metabolites have a half-life of 30 to 60 minutes and are eliminated by the kidney. Pharmacokinetic studies were not conducted. TISSEEL is expected to be completely resorbed in 10 to 14 days.
Because TISSEEL is applied only topically, systemic exposure or distribution to other organs or tissues is not expected.
TISSEEL was evaluated in a prospective, controlled, randomized, single-blind, multicenter clinical study against manual compression with gauze pads in 140 subjects undergoing vascular surgery with expanded polytetrafluoroethylene (ePFTE) graft placement (arterio-arterial bypasses and AV shunts for dialysis access in the upper and lower extremity). Subjects received standardized dosages of heparin. Protamine was administered after the primary endpoint had been assessed. Long-term antiplatelet treatments were continued perioperatively at the surgeon’s discretion.
Subjects were randomly assigned to TISSEEL or control when persistent bleeding at the study suture line was present after surgical hemostasis, i.e., sutures. Eligible bleedings before clamping and treatment application were defined as a minimum of 25% of the suture line bleeds or at least 5 suture line bleedings or any pulsatile or spurting needle hole bleeding. For the primary endpoint, hemostasis achieved at the study suture line at 4 minutes and maintained until surgical closure, a single application of TISSEEL was statistically significantly superior to control (p<0.0001; likelihood ratio chi-square test; 2.5% one sided) [ITT].
| Hemostasis at the study suture line within 4 minutes and maintained until surgical closure | ||
| TISSEEL | Manual Compression | |
| Intent to Treat Analysis | 44/70 (62.9%) | 22/70 (31.4%) |
TISSEEL was evaluated in a prospective, parallel design, randomized (1:1), double-blind, multicenter clinical study against an earlier formulation of the product, TISSEEL VH, in 317 subjects undergoing cardiac surgery requiring cardiopulmonary bypass (CPB) and median sternotomy. Patients were treated with TISSEEL or the control product only when hemostasis was not achieved by conventional surgical methods. For the endpoint, hemostasis achieved at the primary treatment site within 5 minutes of treatment and maintained until closure of the surgical wound, TISSEEL was non-inferior to the earlier formulation of the product using a one-sided 97.5% confidence interval on the difference in the proportion of subjects successfully treated.
| Hemostasis within 5 minutes and maintained until surgical closure | ||
| TISSEEL | TISSEEL VH | |
| Intent to Treat Analysis | 127/144 (88.2%) | 129/144 (89.6%) |
An earlier formulation of TISSEEL was evaluated in an open-label crossover study against control topical hemostatic agents in 489 patients undergoing cardiovascular reoperation or resternotomy at 11 institutions. Patients were randomized to TISSEEL or control hemostatic agents when a topical hemostatic was needed at the conclusion of surgery and after all attempts at surgical hemostasis. Patients were crossed to the alternative therapy if bleeding continued after the 5 minute endpoint. At 10 centers, TISSEEL was used after administration of protamine sulfate. At one site, TISSEEL could be used before administration of protamine sulfate. 365 of the 489 patients developed bleeding episodes requiring treatment. For the endpoint (successful hemostasis at 5 minutes), TISSEEL was statistically significantly superior to control topical hemostatic agents in these patients. Similarly, absolute time to cessation of bleeding was statistically significantly shorter for TISSEEL than for control topical hemostatic agents (p<0.0001, Gehan-Wilcoxon test, two sided).
| Hemostasis within 5 minutes | |
| TISSEEL | Control Topical Hemostatic Agent |
| 82.4% (159/193) | 44.5% (76/172) |
| Pearson χ2 two sided; p <0.0001; intent-to-treat analysis |
In a single center, open label trial, an earlier formulation of TISSEEL was compared to historical controls in patients undergoing laparotomy for blunt or penetrating traumatic injury to the spleen and/or liver. Use of TISSEEL resulted in the need for statistically significantly fewer splenectomies than control hemostatic maneuvers (Refer to Table 9). TISSEEL did not result in significantly reduced mortality in patients with blunt or penetrating trauma to the liver alone or to the liver and spleen (p=0.067, χ2, one sided).
| Splenectomy Rate | |||
| Injury to: | TISSEEL | Historic Controls | |
| Spleen | 0/19 | 14/22 | p <0.001 |
| Spleen and liver | 1/26 | 19/34 | p <0.001 |
In a single center, prospective open label study of 118 patients randomized to standard of care (58 patients) or standard of care plus fibrin sealant (60 patients) for elective colostomy closure after temporary colostomy placement for treatment of traumatic injury to the colon, the earlier version of TISSEEL plus standard of care was also shown to be significantly superior to standard of care alone (p=0.0406, Jonckheere-Terpstra test for ordinal data, two sided) with regard to anastomotic complications (leakage, intra-abdominal abscess formation, re-operation, septic shock, and death).
How Supplied
TISSEEL is supplied in the following pack sizes and presentations:
| Pack Size | TISSEEL Kit (Freeze-Dried) | TISSEEL Kit (Freeze-Dried) with DUPLOJECT System | TISSEEL Pre-Filled Syringe (Frozen) with DUO Set |
| 2 mL | 0944-4210-02 | 0944-4301-02 | 0944-8402-02 |
| 4 mL | 0944-4211-04 | 0944-4302-04 | 0944-8402-04 |
| 10 mL | 0944-4212-10 | 0944-4303-10 | 0944-8402-10 |
TISSEEL Kit contains one vial each of:
1. Sealer Protein Concentrate (Human), Vapor Heated, Solvent/Detergent Treated, Freeze-Dried, Sterile
2. Fibrinolysis Inhibitor Solution, (Synthetic) Liquid, Sterile
3. Thrombin (Human), Vapor Heated, Solvent/Detergent Treated, Freeze-Dried, Sterile
4. Calcium Chloride Solution, Liquid, Sterile
TISSEEL Pre-Filled Dual-Chambered Syringe contains:
1. Sealer Protein Solution, Vapor Heated, Solvent/Detergent Treated, Frozen Solution, Sterile
2. Thrombin Solution, Vapor Heated, Solvent/Detergent Treated, Frozen Solution, Sterile
3. Sterile accessory devices (DUO Set: 1 plunger, 2 joining pieces and 4 application cannulas)
Storage
TISSEEL Kit (Freeze-Dried)
Store at 2 - 25°C. Avoid freezing. Do not freeze or refrigerate reconstituted solutions.
TISSEEL Pre-filled Syringe (Frozen)
Store at ≤ -20°C. Do not refrigerate or re-freeze after thawing.
Do not use after the expiration date. Discard if packaging of any components is damaged.
Discuss the risks and benefits of this product with the patient since it is made from human plasma.
Instruct patients to consult their physician if symptoms of B19 virus infection appear (fever, drowsiness, chills and runny nose) followed about two weeks later by a rash and joint pain (see Use in Specific Populations (8.1)).
Baxter Healthcare Corporation
Westlake Village, CA 91362 USA
US License No. 140
This product is covered by US Patent No. 5,962,405.
Baxter, Duo, Duploject, Easyspray, Fibrinotherm and Tisseel are trademarks of Baxter International Inc.
Fibrin Sealant TISSEEL Frozen 2 mL Unit Carton
NDC 0944-4210-02
Fibrin Sealant
TISSEEL 2 mL
Vapor Heated, Solvent/Detergent Treated, Kit
Contents:
Sealer Protein Concentrate (Human), Vapor Heated, Solvent/Detergent Treated, freeze dried, sterile, for 1 mL of Sealer Protein Solution
Fibrinolysis Inhibitor Solution (Synthetic), sterile, 3000 KIU of Aprotinin /mL
Thrombin (Human), Vapor Heated, Solvent/Detergent Treated, freeze dried, sterile, for 1 mL of Thrombin Solution 500 units mL
Calcium Chloride Solution, sterile, 40 µmoL/mL
The risks and benefits of this product should be discussed with the patient. Read enclosed directions for reconstitution and application before use. Use within four hours of reconstitution.
NOT FOR INJECTION. For single use only.
Not made with natural rubber latex
Rx only
Fibrin Sealant TISSEEL Frozen 2 mL Unit Carton
NDC 0944-4301-02
Fibrin Sealant
TISSEEL 2 mL
Vapor Heated, Solvent/Detergent Treated, Kit
Contents:
Sealer Protein Concentrate (Human), Vapor Heated, Solvent/Detergent Treated, freeze dried, sterile, for 1 mL of Sealer Protein Solution
Fibrinolysis Inhibitor Solution (Synthetic), sterile, 3000 KIU of Aprotinin /mL
Thrombin (Human), Vapor Heated, Solvent/Detergent Treated, freeze dried, sterile, for 1 mL of Thrombin Solution 500 units mL
Calcium Chloride Solution, sterile, 40 µmoL/mL
The risks and benefits of this product should be discussed with the patient. Read enclosed directions for reconstitution and application before use. Use within four hours of reconstitution.
NOT FOR INJECTION. For single use only.
Not made with natural rubber latex
Rx only
Also inlcudes: DUPLOJECT Fibrin Sealant Preparation and Application System 2 mL/4mL
Calcium Chloride Solution Label
NDC 0944-7401-01
Calcium Chloride Solution
Sterile
For reconstitution of freeze-dried
Thrombin (Human), Contents: 1 mL
Concentration: 40 µmoL/mL
NOT FOR INJECTION. Store at 2°C to 25°C.
Baxter Healthcare Corporation
Westlake Village, CA 91362 USA
U.S. License No. 140
Fibrinolysis Inhibitor Solution (Synthetic) Label
NDC 0944-7201-01
Fibrinolysis Inhibitor Solution (Synthetic)
Sterile
For reconstitution of freeze-dried
Sealer Protein Concentrate (Human),
Contents: 1 mL Concentration: 3000 KIU of Aprotinin/mL
NOT FOR INJECTION. Store at 2°C to 25°C.
Baxter Healthcare Corporation
Westlake Village, CA 91362 USA
U.S. License No. 140
Sealer Protein Concentrate (Human) Label
NDC 0944-7112-01
Sealer Protein Concentrate (Human)
Vapor Heated, Solvent/Detergent Treated,
Freeze-Dried, Sterile
Reconstitute with 1 mL of
Fibrinolysis Inhibitor Solution (Synthetic)
Vial contains a stirrer to facilitate reconstitution.
Baxter Healthcare Corporation
Westlake Village, CA 91362 USA
U.S. License No. 140
Rx only
Use within 4 hours of reconstitution.
Read enclosed directions prior to use.
NOT FOR INJECTION.
Store at 2°C to 25°C
Thrombin (Human) Label
NDC 0944-7332-01
Thrombin (Human)
Vapor Heated, Solvent/Detergent Treated,
Freeze-Dried, Sterile
Reconstitute with 1 mL of Calcium Chloride
Solution
Concentration: 500 units/mL
Baxter Healthcare Corporation
Westlake Village, CA 91362 USA
U.S. License No. 140
Rx only
Use within 4 hours of reconstitution.
Read enclosed directions prior to use.
NOT FOR INJECTION.
Store at 2°C to 25°C
Fibrin Sealant TISSEEL 2 mL Syringe Label
Fibrin Sealant
TISSEEL 2 mL
Fibrin Sealant TISSEEL Frozen 4 mL Unit Carton
NDC 0944-4211-04
Fibrin Sealant
TISSEEL 4 mL
Vapor Heated, Solvent/Detergent Treated, Kit
Contents:
Sealer Protein Concentrate (Human), Vapor Heated, Solvent/Detergent Treated, freeze dried, sterile, for 2 mL of Sealer Protein Solution
Fibrinolysis Inhibitor Solution (Synthetic), sterile, 3000 KIU of Aprotinin /mL
Thrombin (Human), Vapor Heated, Solvent/Detergent Treated, freeze dried, sterile, for 2 mL of Thrombin Solution 500 units mL
Calcium Chloride Solution, sterile, 40 µmoL/mL
The risks and benefits of this product should be discussed with the patient. Read enclosed directions for reconstitution and application before use. Use within four hours of reconstitution.
NOT FOR INJECTION. For single use only.
Not made with natural rubber latex
Rx only
Fibrin Sealant TISSEEL Frozen 4 mL Unit Carton
NDC 0944-4302-04
Fibrin Sealant
TISSEEL 4 mL
Vapor Heated, Solvent/Detergent Treated, Kit
Contents:
Sealer Protein Concentrate (Human), Vapor Heated, Solvent/Detergent Treated, freeze dried, sterile, for 2 mL of Sealer Protein Solution
Fibrinolysis Inhibitor Solution (Synthetic), sterile, 3000 KIU of Aprotinin /mL
Thrombin (Human), Vapor Heated, Solvent/Detergent Treated, freeze dried, sterile, for 2 mL of Thrombin Solution 500 units mL
Calcium Chloride Solution, sterile, 40 µmoL/mL
The risks and benefits of this product should be discussed with the patient. Read enclosed directions for reconstitution and application before use. Use within four hours of reconstitution.
NOT FOR INJECTION. For single use only.
Not made with natural rubber latex
Rx only
Also includes: DUPLOJECT Fibrin Sealant Preparation and Application System 2 mL/4mL
Calcium Chloride Solution Label
NDC 0944-7401-02
Calcium Chloride Solution
Sterile
For
reconstitution of freeze-dried
Thrombin (Human), Contents: 2 mL
Concentration: 40 µmoL/mL
NOT FOR INJECTION. Store at 2°C to 25°C.
Baxter Healthcare Corporation
Westlake Village, CA 91362 USA
U.S. License No. 140
Fibrinolysis Inhibitor Solution (Synthetic) Label
NDC 0944-7201-02
Fibrinolysis Inhibitors Solution (Synthetic)
Sterile
For reconstitution of freeze-dried
Sealer Protein Concentrate (Human),
Contents: 2 mL Concentration: 3000 KIU of Aprotinin / mL
NOT FOR INJECTION. Store at 2°C to 25°C.
Baxter Healthcare Corporation
Westlake Village, CA 91362 USA
U.S. License No. 140
Rx only
Sealer Protein Concentrate (Human) Label
NDC 0944-7112-02
Sealer Protein Concentrate (Human)
Vapor Heated, Solvent/Detergent Treated, Freeze-Dried, Sterile
Reconstitute with 2 mL of Fibrinolysis Inhibitor Solution (Synthetic)
Vial contains a stirrer to facilitate reconstitution.
Baxter Healthcare Corporation
Westlake Village, CA 91362 USA
U.S. License No. 140
Rx only
Use within 4 hours of reconstitution.
Read enclosed directions prior to use.
NOT FOR INJECTION.
Store at 2°C to 25°C
Thrombin (Human) Label
NDC 0944-7332-02
Thrombin (Human)
Vapor Heated Solvent/Detergent Treated,
Freeze-Dried, Sterile
Reconstitute with 2 mL of Calcium Chloride
Solution
Concentration: 500 units/mL
Baxter Healthcare Corporation
Westlake Village, CA 91362 USA
U.S. License No. 140
Rx Only
Use within 4 hours of reconstitution.
Read enclosed directions prior to use.
NOT FOR INJECTION.
Store at 2°C to 25°
Fibrin Sealant TISSEEL 4 mL Syringe Label
Fibrin Sealant
TISSEEL 4 mL
Fibrin Sealant TISSEEL Frozen 10 mL Unit Carton
NDC 0944-4212-10
Fibrin Sealant
TISSEEL 10 mL
Vapor Heated, Solvent/Detergent Treated, Kit
Contents:
Sealer Protein Concentrate (Human), Vapor Heated, Solvent/Detergent Treated, freeze dried, sterile, for 5 mL of Sealer Protein Solution
Fibrinolysis Inhibitor Solution (Synthetic), sterile, 3000 KIU of Aprotinin /mL
Thrombin (Human), Vapor Heated, Solvent/Detergent Treated, freeze dried, sterile, for 5 mL of Thrombin Solution 500 units mL
Calcium Chloride Solution, sterile, 40 µmoL/mL
The risks and benefits of this product should be discussed with the patient. Read enclosed directions for reconstitution and application before use. Use within four hours of reconstitution.
NOT FOR INJECTION. For single use only.
Not made with natural rubber latex
Rx only
Fibrin Sealant TISSEEL Frozen 10 mL Unit Carton
NDC 0944-4303-10
Fibrin Sealant
TISSEEL 10 mL
Vapor Heated, Solvent/Detergent Treated, Kit
Contents:
Sealer Protein Concentrate (Human), Vapor Heated, Solvent/Detergent Treated, freeze dried, sterile, for 5 mL of Sealer Protein Solution
Fibrinolysis Inhibitor Solution (Synthetic), sterile, 3000 KIU of Aprotinin /mL
Thrombin (Human), Vapor Heated, Solvent/Detergent Treated, freeze dried, sterile, for 5 mL of Thrombin Solution 500 units mL
Calcium Chloride Solution, sterile, 40 µmoL/mL
The risks and benefits of this product should be discussed with the patient. Read enclosed directions for reconstitution and application before use. Use within four hours of reconstitution.
NOT FOR INJECTION. For single use only.
Not made with natural rubber latex
Rx only
Also includes: DUPLOJECT Fibrin Sealant Preparation and Application System 10 mL
Calcium Chloride Solution Label
NDC 0944-7401-05
Calcium Chloride Solution
Sterile
For reconstitution of freeze-dried Thrombin (Human)
Contents: 5 mL, Concentration: 40 µmoL/mL
Baxter Healthcare Corporation
Westlake Village, CA 91362 USA
U.S. License No. 140
Rx Only
NOT FOR INJECTION.
Store at 2°C to 25°C.
Sealer Protein Concentrate (Human) Label
NDC 0944-7112-05
Sealer Protein Concentrate (Human)
Vapor Heated, Solvent/Detergent Treated, Freeze-Dried, Sterile
Reconstitute with 5 mL of Fibrinolysis Inhibitor Solution (Synthetic)
Vial contains a stirrer to facilitate reconstitution.
Baxter Healthcare Corporation
Westlake Village, CA 91362 USA
U.S. License No. 140
Rx only
Use within 4 hours of reconstitution.
Read enclosed directions prior to use.
NOT FOR INJECTION.
Store at 2°C to 25°C.
Thrombin (Human) Label
NDC 0944-7332-05
Thrombin (Human)
Vapor Heated, Solvent/Detergent Treated,
Freeze-Dried, Sterile
Reconstitute with 5 mL of Calcium Chloride Solution
Concentration: 500 units/mL
Baxter Healthcare Corporation
Westlake Village, CA 91362 USA
U.S. License No. 140
Rx only
Use within 4 hours of reconstitution.
Read enclosed directions prior to use.
NOT FOR INJECTION.
Store at 2°C to 25°C.
Fibrin Sealant TISSEEL 10 mL Syringe Label
Fibrin Sealant
TISSEEL 10 mL
|
TISSEEL
fibrinogen human and thrombin human kit | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
|
|
TISSEEL
fibrinogen human and thrombin human kit | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
|
|
TISSEEL
fibrinogen human and thrombin human kit | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
|
|
TISSEEL
fibrinogen human and thrombin human kit | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
|
|
TISSEEL
fibrinogen human and thrombin human kit | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
|
|
TISSEEL
fibrinogen human and thrombin human kit | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
|
|
TISSEEL
FROZEN fibrinogen human and thrombin human solution | ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
|
| Labeler - Baxter Healthcare Corporation (039121363) |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| Baxter Aktiengesellschaft | 300434670 | MANUFACTURE |


Tycho Graph Editors
Class Documentation
Tycho Home Page
Copyright © 1996-1997, The Regents of the University of California. All rights reserved.
Last updated: $Date$ comments to:
tycho@eecs.berkeley.edu


--- layout: page title: "Something about me" description: "Hi, this is Jasmine." header-img: "img/post-bg-rwd.jpg" ---
A statistical programmer working in Tokyo.
6-years' experiences in Clinical Trial.
Hi, This is Jasmine , a statistical programmer and currently working in Tokyo.
This is my personal blog, making with Github Pages and Jekyll. My GitHub 👉 Github·Jasmine. I would like to record and share experiences or useful programs in my daily work.
I have been working in several cities: Guangzhou, HongKong, Shanghai and Tokyo. It was interesting experience to visit and explore a new city.
I love my job as a statistical programmer in clinical trials. Whenever a new drug gain approval to the market to relieve people's pain, I know what I am doing is worthwhile.


Nothing allowed after end token. To continue a command, put it on the line with the <<
.
cat << EOF
Hello
EOF | nl
cat << EOF | nl
Hello
EOF
You have a here document, and appear to have added text after the terminating token.
This is not allowed. If it was meant to continue the command, put it on the line with the <<
.
If it helps, look at << "END" as if it was < file, and make sure the resulting command is valid. This is what the shell does. You can then append here document data after the command.
None


{% extends "forum/base.html" %} {% block content %} {% include "forum/post/crumbs.html" %}
{% if post.is_spam %} Your post was made, but was flaged as spam. It will have to be reviwed by an admin before being made public. Return to Thread {% elif not post.is_public %} Your post was made, but will not be public till it has been view by an administrator. Return to Thread {% else %} Thank you for posting at our forums! You will be directed back to your post in {{ forums.post_redirect_delay }} second{{ forums.post_redirect_delay|pluralize }}. View Your Post {% endif %}


To view this page ensure that Adobe Flash Player version
${version_major}.${version_minor}.${version_revision} or greater is installed.
What is this?
Bfxr is an elaboration of the glorious
Sfxr, the program of choice for many people looking to make sound effects for computer games.
Bfxr has moved in the direction of increased complexity and range of expression. All the buttons that you know and love are here, but there are some new things as well:
- 5 new waveforms : triangle, breaker, tan, whistle, and pink noise.
- 3 new filters : compression, harmonics, and bitcrusher.
- Ability to lock parameters during mutation/randomization.
- Expanded pitch-jumping abilities - good for arpeggiation effects.
- Visualisation
- Mixer
- Keeps your sounds and mixes in persistant lists.
- Can reverse synths
- Ability to link directly to sounds
You have full rights to all sounds made with bfxr, and are free to use them for any purposes, commercial or otherwise.
If you use this for anything cool, or have any suggestions for improvements, or bugs to report, please
drop me a mail or leave a comment.
For what it's worth, most of the work on this version was done by me,
increpare. If you appreciate the work I've done, consider
supporting it on patreon.
Secrets!
Shortcuts
- Ctrl+C / Ctrl+V to copy/paste (or Cmd + C/Cmd + V if you're on a Mac).
- Enter/Return to play.
Tips
- If you click on the text beside one of the sliders, it moves the slider back to its default position.
- If you right-click one of the locks, it locks/unlocks all parameters
- you can clear out all your sound lists from by selecting "Clear All" from the Load dropdown menu
- There's some handy info in the tooltips.
- If you don't want to download Adobe AIR for the privilege of a standalone version, you can safely just download this webpage to your hard disk and run it locally.
- You may find it gets slow or stutters sometimes. If you hit play a second time it should play just fine. A chief cause of slowness is use of the 'harmonics' parameter in the synth screen. It's tres beautiful, but be careful with it.
- Running multiple copies at once is DANGEROUS, only the data from one of them will remain. So be careful about opening lots of links to sounds that people have made all at once. However, and this is the tip part: you can paste the URL in with the paste faculty as well (via the button, or ctrl+v).
- The presets only traverse a small portion of the sonic range of this program. Try playing around with parmeters, layering them in the mixer, see what happens :)
- If you like the sounds you've made with this, consider putting them into a game, eh? 'tis not hard nowadays to toss a game together.
Confusing.
Nah, it's not that bad. You can restrict yourself to using the preset buttons, or working entirely from the mixer tab. Paying attention to the tooltips might help.
But, you know, if you want something more easy going, try out this program's inspiration:
as3sfxr. It's a direct port of the original Sfxr for flash, and it's totally great and has a whole lot less buttons and sliders than Bfxr.
Code + API
I've put the code up on github
This is released under the
Apache Licence 2.0.
As with
Tom's version, the code is quite modular and can be easily incorporated into any as3 project.
The idea is that you can take the strings that you get by clicking 'copy' in the editor, and pass
them as strings to the Bfxr object. The best usage is to pre-cache them using a cache function (with
an optional callback, if you want it to spread the calculation over several frames).
It also has the ability to cache several mutations of a single object at run-time. This can be good for getting a reach-feeling environment, and cuts down on the usual repeitition of sound-effects. While mutating, it will respect any locks applied to the parameters in the editor, to allow for an additional degree of control over the mutation.
Let me know if you do anything cool with it!
Credits
Archaeology
I don't know if it's related, but I believe that _why made a program called sound foley (which I haven't been able to get to work) which looks quite similar to Sfxr in design based on what I've seen of his _why's presentation of it.
The darling DrPetter made the program this is based on, Sfxr:
The fabulous Tom Vian did a flash port of this, called as3sfxr
There's also a port of Sfxr to OS X that's quite loved by people (and was a little influential) called cfxr:
I did a mod of as3sfxr that introduced some new features, and called it as3sfxr-b:
After asking for feedback, I spent some time adding and changing more things, making something new. Which is Bfxr. Which is what you see on this page.
Code from
Bulk of coding of this version done by
poor little me.
In addition to code from Tom/DrPetter, code snippits taken from
Thanks + Acknolwedgements
- DrPetter, for Sfxr.
- Tom Vian, for his elegantly constructed as3sfxr port.
- @docky, @Draknek, @KommanderKlobb, @eigenbo, @GrimFang4, @nyarla, @bfod, @jasperbyrne, @draknek, @hybridmind, @RinkuHero, DustinGunn, mcc, and agj for feedback + suggestions. And Derek for some early encouragement.
- The people from the #flex irc room on freenode for technical help in my hour of need, especially J_A_X.
Other software that can be software for making sounds:
Comments


13-year-old prodigy to participate in Formula 4 championship in 2020!
by Nicolás Quarles van UffordWe all remember Max Verstappen winning a Formula 3 race aged 16 in May of 2014, becoming the youngest driver ever to do so, but that record could be shattered in due time, as 13-year-old talent Juju Noda is set to compete in Danish Formula 4 next year!
The name Noda should ring a bell for F1 fans, as Juju is the daughter of former F1 driver Hideki Noda, who was active in the sport in 1994.
Juju already has some experience driving a Formula 3 car, but the regulations state there is a minimum age to compete in the junior category, which is 15. This means she could participate in F3 in 2021, which makes Danish Formula 4 a good way to prepare for 2021.
The Japanese prodigy already has experience competing in similar equipment to F3, as she took part in the Japanese under 17 championships. She drove in that championship for her dad's team: Noda Racing.
Check out this video that was made on Juju Noda last year!


艺术舌尖，食尚领鲜
- 营
- 养
- 美
- 味
- 吃
- 出
- 健
- 康
Spring bamboo shoots are long lush,how can in the day of the spring with less use of bamboo shoots to cook?Bamboo shoots for evergreen perennial herbs,edible part is the primary,fat,s
hort strong young or whip.Private bamboo shoots of bu


I am a experienced developer currently working as a consultant for Knightec. I mostly work frontend directly with the UI, regardless if it's for mobile apps or websites. My largest experience is in React. I have 11 years of experience as a basketball coach which very effectively has given me leadership experience.
Part of the Men's U15 and U16 coaching staff
Mentor for other coaches, helping other coaches improve.
Senior Men's team in Stockholm, Sweden.
Two weeks in Stockholm, Sweden.
Men's U19 in Stockholm, Sweden.
Six months in Stockholm, Sweden.
One week in San Antonio, Texas.
One week in San Antonio, Texas.
Responsible for two age groups: Boys U14 and U15 in Stockholm, Sweden.
Responsible for Boys U16 two years in a row.
Boys U17 in Stockholm, Sweden.
Boys U16 in Stockholm, Sweden.
Boys U12-U14 in Stockholm, Sweden.
Boys U13 in Stockholm, Sweden.
Boys U12 in Stockholm, Sweden.
 I've coached for about 10 years at a basketball club in Stockholm, Central Basket. I've also coached for Stockholm's district and regional teams. Currently I am also part of the coaching staff for Sweden's Men's U16 National Team.
When computer programming and basketball is put aside I really enjoy watching movies and spending time with people I care about.
I do however put a lot of work into basketball and watch several basketball clinics each month.


---
layout: post
title: Mason and YUI
tags:
- Perl
- Software Development
- Web
status: publish
type: post
published: true
meta: {}
---
I will be contributing some new work at soon at Unisolve which will revolve around HTML::Mason and the Yahoo! User Interface Library (YUI). I am really looking forward to digging further into these tools.
Mason is a templating engine for Perl programmers. That means that you can mix Perl code with your data (often HTML) so that additional content can be generated in the fly before the information is presented. For instance you can extract records from a database. There are a plethora of these tools, however Mason is one of the more established.
YUI is a AJAX library designed to allow web applications to present a rich user interface using Javascript (and other stuff) on the browser. This can make web applications provide features and functions that have only be possible previously with "thick" client software that have enough programmed intelligence to support the user interaction experience.


Be first to get them
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s
Read more
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s
Read more
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s
Read more
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s
Read more


The domain name "bitcoin.org" was registered on 18 August 2008.On 31 October 2008, a link to a paper authored by Satoshi Nakamoto titled Bitcoin: A Peer-to-Peer Electronic Cash System was posted to a cryptography mailing list. Nakamoto implemented the bitcoin software as open-source code and released it in January 2009 Nakamoto's identity remains unknown. It was worth 8 cents when it first came out but in 10 years skyrocketed to 8,092 dollars which means that those who bought multiple then would have certainly made a fortune now.


Shop
About
Contact
Store Front
Login
Store Details
Font
Colors
Background Images
Product Upload
Products
Store Name
Store Details
About
Store Address
Submit
Font
Choose...
Font 1
Font 2
Font 3
Font 4
Font 5
Options
Header Font Color
Body Font Color
Footer Font Color
Submit
Store Color
Submit
Background Image
Choose file
Upload
About Image
Choose file
Upload
Product Name
Price
Inventory
Description
Product Image
Choose file
Upload
Submit
Product List
Product Name
Product Name
Product Name


Living abroad is hard. Cultural differences can lead to a lot of initial awkwardness and confusion. We aim to solve that problem by informing people of what is to come. By selecting the country you are moving from and the country you are moving to, we customize the results to show information relevant to you depending on where you're coming from, saving you time.
Prototype created by: Allison Alder, Carlos Saldaña, and Felix Kieber
HCI Design Project


Homepage
change nav
Exchange Platform
Home
My Account
My Points
List Of Companies
Exchange Center
Notifications
Logout
NEWS !
description about news
View More


--- layout: post status: publish published: true title: VS 2005 Prices Revealed author: display_name: Tomas Restrepo login: tomasr email<EMAIL_ADDRESS>url: http://winterdom.com/ author_login: tomasr author_email<EMAIL_ADDRESS>author_url: http://winterdom.com/ wordpress_id: 607 wordpress_url: http://winterdom.com/2005/03/vs2005pricesrevealed date: '2005-03-23 15:58:57 +0000' date_gmt: '2005-03-23 15:58:57 +0000' categories: - ".NET" tags: [] comments: [] ---
The prices for the upcoming SKUs of VS 2005 and MSDN have been revealed now. Yikes! Those seem just waaaayyy to high.
The good part of it is: thank goodness I haven't looked too deeply into what is offered in the team editions of VS 2005 (and especially the architects one), as it would be a complete waste of time. At those prices, I'm never gonna see one of those installed on my work machine, which is a pity, because it seems to have wonderful and much needed tools.
Well, guess at this rate, I'd better start looking for replacement tools, since we're probably need them :(
Note: Yes, I realize fully that for many large corporations, those kind of prices might be workable. But, if you live in a third world country, like me, and work in a company with highly distributed teams (meaning each project team usually moves out of the main office into the client premises bringing everything they need with them), that kind of licensing sounds like a no-go right from the start. Those prices make absolutely no sense for a market like us, and pretty much would leave ISVs / Systems Integrators out in the cold. It's a pity....


Straub nurses picket outside the hospital over contract issues | Honolulu Star-Advertiser
More than 50 Straub nurses gathered along the busy intersection of South King Street and Ward Avenue today to picket outside the hospital over contract issues.
The Hawaii Nurses Association, representing 450 registered nurses at Straub Medical Center, have been picketing since Saturday. Nurses have been working without a contract since Nov. 1.
Daniel Ross, president of the Hawaii Nurses Association, OPEIU Local 50, said Straub nurses will continue to picket today and tomorrow to draw attention to Hawaii Pacific Health’s “strict and punitive attendance policy.”
“Their major issue is the archaic attendance policy,” Ross said today. “If you call in sick twice in one month, you get disciplined. You call in [sick] three times in six months, you get disciplined. The result of it is that it causes workers to come to work sick, saying it’s not safe, it’s not right. When workers come to work sick, they can get their patients sicker … people should not be penalized for getting sick.”
Straub CEO Art Gladstone, chief nurse executive for parent company Hawaii Pacific Health, on Friday told the Star-Advertiser the hospital has been negotiating in “good faith” with the nurses union and has offered a settlement that provides fair wages and benefits consistent with other HNA contracts.
“Our policies and procedures are standardized to ensure fairness for all employees and the care and safety of our patients,” he said. “We believe our attendance policy is fair and equitable for all of our 7,000+ employees throughout Hawaii Pacific Health. As a health care organization, the well-being of both our patients and our employees are among our top priorities.”
Negotiations are scheduled to resume tomorrow.


{{ define "main"}}
We're sorry you ended up here. Sometimes a page gets moved or deleted, but hopefully we can help you find what you're looking for. What next?
To do:


App-Directory Structure¶
├── .gitignore
├── .pre-commit-config.yaml
├── README.md
├── __main__.py
├── app.py
├── args.py
├── install.json
├── log
│ ├── app.log
│ ├── message.tc
│ ├── run.log
├── playbook_app.py
├── pyproject.toml
├── requirements.txt
├── run.py
├── setup.cfg
├── tcex.d
│ ├── data
│ └── profiles
│ └── simple_data.json
└── tcex.json
.gitignore (optional)¶
This template file specifies intentionally untracked files that Github should ignore. This file is part of the template update, but it optionally can be updated, if required.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 | #=================================================
# Python App Template
# Version: 1.0.4
# Last Updated: 2019/03/06
#=================================================
#-------------------------------------------------
# Language Exclusions
#-------------------------------------------------
__pycache__
*.pyc
.env
venv
#-------------------------------------------------
# App Specific Exclusions
#-------------------------------------------------
*.log
local-*
log
sample-*.json
#-------------------------------------------------
# Build Exclusions
#-------------------------------------------------
build
lib_*
permutations.json
target
temp
#-------------------------------------------------
# IDE Exclusions
#-------------------------------------------------
.c9
.idea
.project
.python-version
.settings
.vscode
*.iml
nbproject
*.swp
*.vim
#-------------------------------------------------
# OS Exclusions
#-------------------------------------------------
.DS_Store
#-------------------------------------------------
# Test Exclusions
#-------------------------------------------------
.coverage
.pytest_cache
artifacts
junit.xml
py36.xml
py37.xml
py38.xml
dump.rdb
#-------------------------------------------------
# Other Nonsense
#-------------------------------------------------
#*************************************************
# Custom Exclusion (per App exclusions)
#*************************************************
|
.pre-commit-config.yaml (optional)¶
This is the configuration file for the pre-commit
Python CLI tool. This configuration is the same one that is used for the internal development of Apps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 | exclude: ^lib
repos:
- repo: https://github.com/pre-commit/pre-commit-hooks
rev: v2.4.0
hooks:
- id: check-added-large-files
args: ["--maxkb=500"]
- id: check-ast
- id: check-builtin-literals
- id: check-case-conflict
- id: check-docstring-first
- id: check-json
- id: check-merge-conflict
- id: check-symlinks
- id: check-toml
- id: debug-statements
- id: double-quote-string-fixer
- id: end-of-file-fixer
- id: mixed-line-ending
- id: no-commit-to-branch
args:
- --branch
- master
- --branch
- qa
- id: pretty-format-json
args:
- --autofix
exclude: ^tests/.+/profiles.d/.*
- id: requirements-txt-fixer
- id: trailing-whitespace
- repo: https://github.com/pycqa/bandit
rev: 1.6.2
hooks:
- id: bandit
args: [--exclude, tests]
- repo: https://github.com/psf/black
rev: 19.10b0
hooks:
- id: black
- repo: https://gitlab.com/pycqa/flake8
rev: 3.8.3
hooks:
- id: flake8
- repo: https://github.com/pre-commit/mirrors-isort
rev: v5.1.3
hooks:
- id: isort
- repo: https://github.com/pycqa/pydocstyle
rev: 5.0.2
hooks:
- id: pydocstyle
- repo: https://github.com/asottile/pyupgrade
rev: v2.7.1
hooks:
- id: pyupgrade
args:
- --py3-plus
- --py36-plus
- repo: https://github.com/yunojuno/pre-commit-xenon
rev: v0.1
hooks:
- id: xenon
args:
[
"--max-average=B",
"--exclude=local*",
"--ignore=lib_*,local*,target,tests",
]
- repo: local
hooks:
- id: pylint
entry: pylint
exclude: ^lib
language: system
name: pylint
types: [python]
|
README.md (required)¶
The README.md
file should contain any relevant information for the App and the App release notes.
1 2 3 4 | # Release Notes
## 1.0.0 (YYYY-MM-DD)
* Initial Release
|
__main__.py (required)¶
This template file should not be modified.
1 2 3 4 5 6 | """Legacy "main" file for running App"""
# first-party
from run import run
# call the run method
run()
|
app.py (required)¶
This file contains the “main” App logic and the run()
method that is called by default. It also can contain methods for tc_actions.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 | """ThreatConnect Playbook App"""
# first-party
from playbook_app import PlaybookApp # Import default Playbook App Class (Required)
class App(PlaybookApp):
"""Playbook App"""
def run(self) -> None:
"""Run the App main logic.
This method should contain the core logic of the App.
"""
def write_output(self) -> None:
"""Write the Playbook output variables.
This method should be overridden with the output variables defined in the install.json
configuration file.
"""
|
args.py (required)¶
This file contains the args required for the App to function properly. Only App args are required to be defined. The default args are part of the TcEx framework and are added automatically.
1 2 3 4 5 6 7 8 9 | """Playbook Args"""
from argparse import ArgumentParser
class Args:
"""Playbook Args"""
def __init__(self, parser: ArgumentParser):
"""Initialize class properties."""
|
install.json (required)¶
This is the main configuration file for the App and controls what inputs and outputs will be presented to the user.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 | {
"allowOnDemand": true,
"displayName": "JSON Pretty",
"features": [
"aotExecutionEnabled",
"appBuilderCompliant",
"secureParams"
],
"languageVersion": "3.6",
"listDelimiter": "|",
"note": "Take raw JSON string and output \"pretty\" with provide indent level.",
"params": [
{
"label": "JSON Data",
"name": "json_data",
"note": "The JSON data to be formatted.",
"playbookDataType": [
"KeyValue",
"KeyValueArray",
"String",
"StringArray",
"TCEntity",
"TCEntityArray"
],
"required": true,
"sequence": 1,
"type": "String",
"validValues": [
"${TEXT}"
]
},
{
"default": "4",
"label": "Indent",
"name": "indent",
"note": "The number of spaces to use for indention (default: 4).",
"playbookDataType": [
"String"
],
"sequence": 2,
"type": "String",
"validValues": [
"${TEXT}"
]
},
{
"default": false,
"label": "Sort Keys",
"name": "sort_keys",
"note": "Indicates whether keys should be sorted.",
"sequence": 3,
"type": "Boolean"
}
],
"playbook": {
"outputVariables": [
{
"name": "json.pretty",
"type": "String"
}
],
"type": "Utility"
},
"programLanguage": "PYTHON",
"programMain": "run",
"programVersion": "1.0.0",
"runtimeLevel": "Playbook"
}
|
log (temporary)¶
This directory is created when running a testing profile locally. All App output is written to this directory, as well as the output from the test cases.
log/app.log (temporary)¶
This log file contains the logging output of the App.
log/message.tc (temporary)¶
This file contains the App exit message. The contents of this file will be displayed in the UI when the App is run the in platform. For local testing, the file should be verified to have content on successful App completion and on failure.
log/run.log (temporary)¶
This log file contains the output from the tcrun
command and will contain information about validation rules.
playbook_app.py (required)¶
This template file contains base logic for a Playbook App. This file should not be edited and will get updated when using the tcinit --action update --template <template name>
command.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 | """Playbook App Template."""
# first-party
from args import Args
from tcex import TcEx
class PlaybookApp:
"""Playbook App Class."""
def __init__(self, _tcex: TcEx):
"""Initialize class properties."""
self.tcex: TcEx = _tcex
# properties
self.args = None
self.exit_message = 'Success'
# automatically parse args on init
self.parse_args()
def parse_args(self) -> None:
"""Parse CLI args."""
Args(self.tcex.parser)
self.args: object = self.tcex.args
def run(self) -> None:
"""Run the App main logic."""
self.tcex.log.info('No run logic provided.')
def setup(self) -> None:
"""Perform prep/setup logic."""
# run legacy method
if hasattr(self, 'start'):
self.tcex.log.warning('calling legacy start method')
self.start() # pylint: disable=no-member
self.tcex.log.trace('setup')
def teardown(self) -> None:
"""Perform cleanup/teardown logic."""
# run legacy method
if hasattr(self, 'done'):
self.tcex.log.warning('calling legacy done method')
self.done() # pylint: disable=no-member
self.tcex.log.trace('teardown')
def write_output(self) -> None:
"""Write the Playbook output variables."""
self.tcex.log.info('No output variables written.')
|
pyproject.toml (optional)¶
This is a Python tool configuration file that contains the configuration for the black formatting tool used to format all Python code.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 | [tool.black]
line-length = 100
skip-string-normalization = true
[tool.pylint.master]
init-hook = "import sys;sys.path.insert(0, 'lib_latest')"
[tool.pylint.messages_control]
# C0103 - invalid-name
# C0116 - missing-function-docstring
# C0302 - too-many-lines
# C0330 - bad-continuation
# C0401 - wrong-spelling-in-comment
# C0411 - wrong-import-order
# E0401 - import-error (checked after tclib)
# R0801 - duplicate-code
# R0902 - too-many-instance-attributes
# R0903 - too-few-public-methods
# R0904 - too-many-public-methods
# R0912 - too-many-branches
# R0913 - too-many-arguments
# R0914 - too-many-locals
# R0915 - too-many-statements
# W0511 - fixme
# W0703 - broad-except
# W1203 - logging-fstring-interpolation
disable = "C0103,C0116,C0302,C0330,C0401,C0411,E0401,R0801,R0902,R0903,R0904,R0912,R0913,R0914,R0915,W0511,W0703,W1203"
[tool.pytest.ini_options]
junit_family = "xunit2"
|
requirements.txt (required)¶
This file contains all the required Python dependencies for the App. The requirements.txt file is used by the tclib
command to build the lib_x.x.x directories.
1 | tcex>=2.0.0,<2.1.0
|
run.py (required)¶
This template file is called by ThreatConnect to launch the App. This file should not be edited and will get updated when using the tcinit --action update --template <template name>
command.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 | """Playbook App"""
# standard library
import traceback
# first-party
from app_lib import AppLib
# pylint: disable=no-member
def run() -> None:
"""Update path and run the App."""
# update the path to ensure the App has access to required modules
app_lib = AppLib()
app_lib.update_path()
# import modules after path has been updated
# third-party
from tcex import TcEx # pylint: disable=import-outside-toplevel
# first-party
from app import App # pylint: disable=import-outside-toplevel
tcex = TcEx()
try:
# load App class
app = App(tcex)
# perform prep/setup operations
app.setup(**{})
# run the App logic
if hasattr(app.args, 'tc_action') and app.args.tc_action is not None:
# if the args NameSpace has the reserved arg of "tc_action", this arg value is used to
# triggers a call to the app.<tc_action>() method. an exact match to the method is
# tried first, followed by a normalization of the tc_action value, and finally an
# attempt is made to find the reserved "tc_action_map" property to map value to method.
tc_action: str = app.args.tc_action
tc_action_formatted: str = tc_action.lower().replace(' ', '_')
tc_action_map = 'tc_action_map' # reserved property name for action to method map
# run action method
if hasattr(app, tc_action):
getattr(app, tc_action)()
elif hasattr(app, tc_action_formatted):
getattr(app, tc_action_formatted)()
elif hasattr(app, tc_action_map):
app.tc_action_map.get(app.args.tc_action)() # pylint: disable=no-member
else:
tcex.exit(1, f'Action method ({app.args.tc_action}) was not found.')
else:
# default to run method
app.run(**{})
# write requested value for downstream Apps
app.write_output() # pylint: disable=no-member
# perform cleanup/teardown operations
app.teardown(**{})
# explicitly call the exit method
tcex.playbook.exit(msg=app.exit_message)
except Exception as e:
main_err = f'Generic Error. See logs for more details ({e}).'
tcex.log.error(traceback.format_exc())
tcex.playbook.exit(1, main_err)
if __name__ == '__main__':
# Run the App
run()
|
setup.cfg (optional)¶
This file contains Python configurations data, specifically for linting ignores or excludes.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 | [flake8]
max-line-length = 100
ignore = E402,W503
[isort]
# profile = "black"
force_grid_wrap = 0
ensure_newline_before_comments = true
import_heading_stdlib = standard library
import_heading_firstparty = first-party
import_heading_thirdparty = third-party
include_trailing_comma = true
known_first_party = api_service_app,app,app_lib,args,external_app,job_app,playbook_app,run,service_app
known_third_party = falcon,pytest,tcex
line_length = 100
multi_line_output = 3
use_parentheses = true
[pep8]
max-line-length = 100
ignore = E203,E402,W503
[pydocstyle]
ignore = D104,D202,D203,D213,D301,D400,D406,D407,D413,D415
|
tcex.json (required)¶
This is the main TcEx framework configuration file. It is required to run local testing and for packaging, but it should not be included in the App package.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 | {
"package": {
"app_name": "TCPB_-_",
"excludes": [
".gitignore",
".pre-commit-config.yaml",
"local-*",
"pyproject.toml",
"setup.cfg",
"tcex.json",
"*.install.json",
"tcex.d"
],
"outdir": "target"
}
}
|


Toggle navigation
Cover to Cover
Account
Book Bag
Book Bag
Book
Description
Price
Options
This is what a description will look like.
$19.99
This is what a description will look like.
$19.99
This is what a description will look like.
$19.99
Checkout
Order Summary
Items:
book 1
$0.00
book 2
$0.00
book 3
$0.00
Shipping:
$0.00
Tax:
$0.00
Total:
$0.00


The other night I found a bottle of the SSRI Zoloft. I found info from various websites what this chemical does to you, how much to take, etc. Normally I donít take Zoloft.
At around 9:50 I took one 50 mg pill of Zoloft. I downed the pill and went out with my mom to do random shit: got lunch, returned some clothes, etc. I noticed around 45 mins to an hour later when we were in the car, I started getting much happier than I was the previous two days. This doesnít mean I was EUPHORIC it just means that I wasnít sad, angry, mad or anything. I got home and I decided this was just a feel of it. at around 1 pm, I downed 4 more pills; I total of 250 mg in all now. Within Iíd say about an hour I was very JITTERY, which I still am 6 hours later. I had a little difficulty focusing, but then I realized the fun. I closed and my eyes and got some awesome closed eye visuals. I opened them and stared at the window with the sunlight coming in, and I closed them, and I suddenly saw a large bright colored, intertwining square; due to the window panes Iím assuming.
It is now 4:30 and I just began to eat something, but suddenly I became struck by a nausea that was VERY aggitating. I went to the bathroom and threw up what I was eating. But now hereís the cool part; even though I didnít like throwing up, I didnít hate it. It didnít make me mad, or agitated, nothing really. This feeling of emotionless is kinda cool but very odd. I do feel happy. Not euphoria like I said before, not even a well being, but the previous 2 days had been extremely stressful with SATs, and an incident at a friendís house; with the Zoloft it was gone. I donít feel that pressure or weight. Its very peculiar.
Another thing is my body feel. I feel slightly different, in terms of body weight. The way I feel when Iím just coming on to a dxm trip. My thoughts are basically the same except very fast. Iím guessing that this is some sort of stimulant in one way or another, because my typing is about 2-3 times as fast, and Iím doing small things that I normally donít do, such as tap my finger against the desk, or shake my foot.
One last thing that Iím noticing is that music is affecting me alot, without my knowing. Iíll explain: about to minutes ago I was playing Ott - splitting an atom, which the music, I feel, sounds like an end to something, like a conclusion. Its almost depressing. Well without my knowing it made me slightly unhappy, which I just picked up on. I changed the track to infected mushroom - spiritual trance, to see if I get slightly amped up, and if my Idea of the music affecting me is correct.
9 minutes later: Yes, I was right, it is very powerful, I feel almost immortally strong I think. Iím getting slightly nauseas again not sure why. My eyes are immensely dilated, but not blood shot. CEVs are still present and Iím getting tracers of bright lights. I feel unbeliveably hyper. I read today that Zoloft stays with you for a few days, but Iíll wait it out and see if it wears off. I donít plan on taking Zoloft again.  I feel tired. I want to get to sleep but I donít think its gonna happen for a long time. Iím not sure why but I think somehow I hit the peak just now, 7 hours later. my thoughts are different, but not amazing. Iím starting to feel lonely but I donít want to be.
Zoloft is very powerful, and very potent.  I donít perticularly like it because I have that ĎIím gonna be like this for a while' feeling. Well Iím gonna go. I hope my report was helpful, but I donít think I can write anymore. I feel like Iím about to crash.
Afterword (2 weeks after 'trip'): I had a strong pang of depression because I let bad thoughts get to me but that was soon washed away, after I finished writing. Iím not sure if it was after affects or the come down of the trip, but for the next few days I still felt it in my system, fairly strong, but waning every day. Sometime last Friday it was completely gone. I had waaay to much trouble sleeping. Its like a cross between low grade acid and speed. I do and I donít recommend it. It kept me up for 2 days straight and my eyes were dilated to full dilation for 4 days. Very weird body buzz, and easy to get depressed, but very impressive for the CEVs, although no open ones. Its got its downsides, so it wasnít really my thing. Think Iíll stick to dxm =)
Experience Reports are the writings and opinions of the individual authors who submit them.
Some of the activities described are dangerous and/or illegal and none are recommended by Erowid.


Dealers
We welcome dealer inquiries! If you would like to contact us about selling Bullseye Strings in your shop, or if you have questions about how we do business, please do not hesitate to give us a call. We will provide quality strings for your customers, and we will not stop until both you and your customers are content with your choice in Bullseye Strings.
Mission
Bullseye Strings offers you custom strings at an affordable price. We have been perfecting our bow strings for quite some time now. All are pre-stretched to 400 pounds in order to ensure dependability and no weak points. In addition, all of our serving is done under a precise number of pounds that we have found works the best to elimnate peep rotation and reduce serving seperation. We offer you a variety of products, in a wide range of colors from BCY 452X and 8190, as well as Brownell XS2 material. Extensive testing has been done, and these materials have been found to be the most stable.
We are here to help all of our fellow archers take the worry out of buying bowstrings; full draw is not the place to wonder if you have the right string. We are a business that is based on the principle of "quality over quantity."
Store Hours: Bullseye Strings is no longer open to the public. This page exists solely to act as part of the online portfolio of websites created by Logan Swango.


{% extends "layout.html" %}
{% block script %}
{% endblock %}
{% block heading %}
Automatic Differentiation Visualization Tool
{% endblock %}
{% block body %}
Welcome! Let's visualize the calculations and computational structure that underlie
automatic differentiation.
To get started, plrease specify the number of input variables and output functions that you would like to visualize.
⚠: This tool only supports up to 3 output functions and up to 5 function input variables. For more complex functions, please use the ADnum, ADmath, and ADgraph modules from the Auto-eD repository.
{% if errors %}


arininfo
- ARINcli Whois Command
arininfo options QUERY_VALUE
This program uses ARIN's Whois-RWS(7) RESTful API to query ARIN's Whois database.
The general usage is "arininfo QUERY_VALUE" where the type of QUERY_VALUE influences the
type of query performed. This program will attempt to guess the type of QUERY_VALUE,
but the QUERY_VALUE type maybe explicitly set using the -t
option. Queries for data
related to the QUERY_VALUE may be specified using the -r
option (i.e. the reverse DNS
delegations related to a network).
In certain cases, Organization handles (orghandle), also knows as organization ids, can be properly determined. This occurs when the Organization handle ends with -z or with -xxx where xxx is a number. As a shortcut for Organization handles that do not match these cases, a -o can be appended to signify that it is an Organization handle.
The following are other criteria for determining the type of the QUERY_VALUE when
the -t
option is not given:
If the QUERY_VALUE is simply a number, it is assumed to be an Autonomous System Number.
If the QUERY_VALUE is a number prepended with "AS", it is assumed to be an Autonomous System Number.
If the QUERY_VALUE begins with "NET-" or "NET6-" it is assumed to be a network handle.
If the QUERY_VALUE appears to be an IPv4 or IPv6 address, then it is assumed to be an IP address.
If the QUERY_VALUE ends in "in-addr.arpa" or "ip6.arpa", it is assumed to be a reverse DNS delegation point.
If the QUERY_VALUE appears to be a proper name, it is assumed to be a name of a Point of Contact.
The QUERY_VALUE can also be a result value from a previous query if it ends with an equal sign ("="). Consider the following tree output:
1= NET-192-136-136-0-1 ( <IP_ADDRESS> - <IP_ADDRESS> )
--- 1. Reverse DNS Delegations
--- 1= 136.136.192.in-addr.arpa.
A QUERY_VALUE of "1=1=1=" would be a shortcut for requerying for 136.136.192.in-addr.arpa. The character between the numbers can also be a period character ("."). So "1.1.1=" would be equivalent.
-r
, --related
TYPE
Query for the specified type related to the query value:
nets
for query for the related networks, dels
for query for the
reverse DNS delegations, orgs
for query for the related organizations,
pocs
for query for the related points of contact, asns
for query for
the related autonomous system numbers
-t
, --type
TYPE
Specify type of the query value:
nethandle
for network handle, pochandle
for point of contact handle,
orghandle
for organization handle, ip4addr
for IPv4 address,
ip6addr
for IPv6 address, ip4cidr
for IPv4 cidr block, ip6cidr
for
IPv6 cidr block, asnumber
for autonomous system number, delegation
for
reverse DNS delegation, pocname
for name of a point of contact,
orgname
for name of an organization, result
for result from a previous query
--pft
YES|NO|TRUE|FALSE
Use a PFT style query.
--cidr
LESS|EXACT|MORE
Type of matching to use for CIDR queries.
--substring
YES|NO|TRUE|FALSE
Use substring matching for name searches.
--details
YES|NO|TRUE|FALSE
Query for extra details.
-U
, --url
URL
The base URL of the Whois-RWS(7) system.
--cache-expiry
SECONDS
Age in seconds of items in the cache to be considered expired.
--cache
YES|NO|TRUE|FALSE
Controls if the cache is used or not.
--messages
MESSAGE_LEVEL
Specify one of the message levels: none
for no messages are to be output,
some
for some messages to be output, or all
for all messages to be output.
--messages-out
FILE
Specifies that messages are to be written to the given file.
--data
DATA_AMOUNT
Specifies the amount of data to be output. Use of of: terse
, normal
,
or extra
.
--data-out
FILE
File where data is to be written if specified.
-V
Equivalent to --messages all
and --data extra
-h
Displays help.
arininfo kosters
queries for a POC with the last name of "Kosters".
arininfo 2=
queries for the second value in a result from the previous query.
arininfo -t orghandle arin
queries for organizations with the handle "arin".
arininfo arin-o
is the same as above.
arininfo <IP_ADDRESS>
queries for the most specific network enclosing
<IP_ADDRESS>.
arincli(7), arinutil(1), Whois-RWS(7)


Turkey has a brand-new bank now. It’s Turkey’s oldest new bank...
The moment our branches open their doors, nearly 30 million bank customers will be greeted by a brand-new attitude.
And not just in Turkey: In 16 countries and 85 locations around the world...
We said “new” but we also now that millions of working and retired folks will feel they already know us very well.
We take as much pride in standing by our country’s artists and athletes as we do the farmers who give life to its soil…
Tomorrow we’ll be sharing in the enthusiasm of courageous entrepreneurs through the thousands of our specialist customer representatives. We’ll be putting our signature to giant projects that will take our country into the future. With our 1,682 branches, 24,000 employees, and more than a century and a half of knowledge and experience, we’ll be striving for much, much more.
Turkey has a brand-new bank now.
It’s Ziraat Bank. Appearing before you with a brand-new attitude and a brand-new look...
Ziraat Bankası.
More than a bank.
If Turkey had a brand-new bank...
And it introduced a brand-new attitude to nearly 30 million customers when it opened its doors tomorrow...
Wouldn’t that be great?
If Turkey had a brand-new bank...
And it financed giant projects that could take our country into the future...
Wouldn’t that be great?
If Turkey had a brand-new bank...
And it shared the enthusiasm of courageous entrepreneurs through its thousands of specialist customer representatives...
Wouldn’t that be great?
If Turkey had a brand-new bank...
And it always met the needs of the farmers who give life to the soil...
Wouldn’t that be great?
If Turkey had a brand-new bank...
And it made our lives easier with services provided by thousands of employees and branches located everywhere in the country...
Wouldn’t that be great?
If Turkey had a brand-new bank...
And it stood closer than ever to millions of pensioners...
Wouldn’t that be great?
If Turkey had a brand-new bank...
And it stood closer than ever to millions of students...
Wouldn’t that be great?
If Turkey had a brand-new bank...
And it always stood by artists and athletes...
Wouldn’t that be great?
If Turkey had a brand-new bank...
And it stood closer than ever to millions of working people...
Wouldn’t that be great?


DISTANCEPOINTEDGE compute distance between a point and an edge DIST = distancePointEdge(POINT, EDGE); Return the euclidean distance between edge EDGE and point POINT. EDGE has the form : [x1 y1 x2 y2], and POINT is [x y]. If EDGE is [Nx4] array, rsult is [Nx1] array computes for each edge. If POINT is [Nx2], then result is computed for each point. If both POINT and EDGE are array, result is [Nx1], computed for each corresponding point and edge. [DIST POS] = distancePointEdge(POINT, EDGE); Also returns the position of closest point on the edge. POS is comprised between 0 (first point) and 1 (last point). See also: edges2d, points2d, distancePoints, distancePointLine --------- author : David Legland INRA - CEPIA URPOI - MIA MathCell created the 07/04/2004.


JenaTool Preferences
Some features of JenaTool are configurable via a standard Eclipse preference
pane, this pane is shown in the figure below.
The following describes these properties in more detail.
- Query Context
-
This defines the context, the set of graphs, over which a query will run. Options
include simply the default graph in the store or the union of all named graphs in
the store.
- SPARQL Results Font
-
Sets the font for the SPARQL Results View, typically this is a monospaced font
for clarity reading table generated by SELECT queries.
- Default RDF Representation
-
Select the output format to use for those query forms that return an RDF Graph.
For example, SELECT queries return tabular data but a DESCRIBE or a CONSTRUCT
will return data as a graph and this property allows you to set the manner in
which the graph is displayed in the results view.


Boy who fractured leg in play area gets €65k settlement
Jamie Cummins was three years old when he fell 2m to the ground in a play and slide area
by Mary CarolanA boy who fell 2m (7ft) to the ground while in a playzone area has settled his High Court action for €65,000.
Jamie Cummins was aged three when he fractured his right thigh bone in the fall as he climbed steps to access the mid-level of a three tier play and slide area at Wexford Playzone.
Jamie Cummins, Mount Prospect, Clonard, Co Wexford, sued Wexford Playzone Ltd, Clonard, Co Wexford as a result of the accident on July 18th, 2015. The case was taken through his mother, Leanne Moore.
The boy was climbing the leatherette covered steps ahead of his mother when he fell down an opening and then down a series of climbing steps to the ground.
He was taken to hospital and a fracture of his right thigh was diagnosed.
The High Court heard liability was at issue in the case. The boy had attended the playzone with his parents and sister.
His mother, the court was told, was right behind her son and arrived at the top behind him.
The mother was assisting the boy’s sister to come up the final step when the accident happened.
Approving the settlement, Mr Justice Garrett Simons noted liability was at issue in the case and he was satisfied to rule the matter as proposed.